CN107788526A - 一种保护骨关节的营养品 - Google Patents
一种保护骨关节的营养品 Download PDFInfo
- Publication number
- CN107788526A CN107788526A CN201711110451.0A CN201711110451A CN107788526A CN 107788526 A CN107788526 A CN 107788526A CN 201711110451 A CN201711110451 A CN 201711110451A CN 107788526 A CN107788526 A CN 107788526A
- Authority
- CN
- China
- Prior art keywords
- raw material
- astaxanthin
- collagen
- nutriment
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 16
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 48
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 47
- 239000001168 astaxanthin Substances 0.000 claims abstract description 47
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 47
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 47
- 102000008186 Collagen Human genes 0.000 claims abstract description 42
- 108010035532 Collagen Proteins 0.000 claims abstract description 42
- 229920001436 collagen Polymers 0.000 claims abstract description 42
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims abstract description 28
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 16
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 16
- 239000011718 vitamin C Substances 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 15
- 206010003246 arthritis Diseases 0.000 claims abstract description 7
- 101100244345 Dunaliella acidophila DHA1 gene Proteins 0.000 claims abstract description 3
- 101100122755 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NPA3 gene Proteins 0.000 claims abstract description 3
- 210000001503 joint Anatomy 0.000 claims description 14
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 7
- 241000168517 Haematococcus lacustris Species 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 3
- 241000238557 Decapoda Species 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 206010060820 Joint injury Diseases 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 2
- 230000009758 senescence Effects 0.000 abstract description 2
- 210000004872 soft tissue Anatomy 0.000 abstract description 2
- 230000003387 muscular Effects 0.000 abstract 2
- 210000001306 articular ligament Anatomy 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 210000001188 articular cartilage Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 5
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 4
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 235000021466 carotenoid Nutrition 0.000 description 4
- 150000001747 carotenoids Chemical class 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 235000012661 lycopene Nutrition 0.000 description 4
- 239000001751 lycopene Substances 0.000 description 4
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 4
- 229960004999 lycopene Drugs 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000006101 laboratory sample Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003244 pro-oxidative effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000002937 blood-testis barrier Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- -1 oxygen radical Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
- A23L33/145—Extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种保护骨关节的营养品,其特征在于,该营养品为组合物,该组合物原料按照重量比分,包括以下组分:虾青素1~100份,胶原蛋白1~5000份,维生素C1~200份,DHA1~100份,EPA1~100份。本发明公开一种可以延缓细胞老化、提高肌肉耐力、抑制关节炎症、增加关节软组织强度及提高滑液的分泌,保护关节组织、对关节损伤进行修复的营养品。对关节炎症有着良好的治愈效果,以及促进关节韧带恢复作用,长期服用能够保护关节组织,抑制炎症,促进关节损伤的修复、提高肌肉耐力。
Description
技术领域
本发明涉及营养食品、保健类药物技术领域,尤其涉及抗氧化、保护骨关节的营养品及其应用。
背景技术
运动员和健身者经常处于韧带和关节拉紧的运动状态,有较高程度导致损伤。随着年龄的增长,骨关节相连组织间的磨损也有导致病变的倾向。而且随着年龄的增长,维护关节的健康也更加困难,而体重超标或者剧烈运动会使情况进一步恶化。
人体在正常的生命活动,是一种氧化活动,有机化合物不完全氧化就会产生自由基。正常状态下人体抗氧化系统会清除自由基,维持机体平衡。然而在激烈运动,高度集中的脑力活动时,由于机体高速运转,耗能大,代谢的供能物质在短时间内消耗大量氧气,会导致自由基大量增加。关节损伤多是由自由基和炎症因子导致。
有研究证实超出通常70%的耗氧活动会产生12倍的自由基,人体抗氧化系统无法及时清除因高耗能高耗氧状态大量产生的自由基,高活性的自由基会夺取细胞的电子,破坏碳水化合物、降解透明质酸、破坏细胞组织、降解蛋白质氨基酸,引发肌体疲劳酸痛及关节炎、筋膜炎、肌腱炎等症状。
因此补充抗氧化剂能清除自由基,对抗自由基的破坏,从而减轻DNA和细胞膜受到的损伤,预防及消除运动后的肌肉肌腱、腱鞘炎症,还能防止透明质酸(关节滑液重要成分)降解,预防及消除运动后的关节炎症,对线粒体细胞起到的抗炎和抗氧化保护作用,能够消除人体疲劳和加快体力恢复。
虾青素(astaxanthin),又名虾黄质、龙虾壳色素,虾青素化学名称:3,3′-二羟基-4,4′-二酮基β-胡萝卜素,色素Aj067-69 CAS No: 472-61-7,分子式C40H52O4,分子量为596.86。
虾青素是一种类胡萝卜素,也是类胡萝卜素合成的最高级别产物,呈深粉红色,化学结构类似于β-胡萝卜素。而β - 胡萝卜素、叶黄素、角黄素、番茄红素等都是类胡萝卜素合成的中间产物,因此在自然界,虾青素具有最强的抗氧化性。广泛存在于生物界,特别是虾、蟹、鱼、藻体、酵母和鸟类的羽毛中含量较高,是海洋生物体内主要的类胡萝卜素之一,其具有以下特性。
超强抗氧化性:虾青素是一种链断裂型抗氧化剂,是目前最强抗氧化剂,其抗氧化能力是维生素E的1000倍,番茄红素的10倍。其具有最全面的“高抗氧化”功效,抗氧化过程非常完整。不像一般的抗氧化剂如β一胡萝卜素、番茄红素、玉米黄质等,仅仅是简单的中和了体内的自由基。这些“中和后分子”将一直停留并堆积在体内,缺少完善的处理,反而成为“助氧化剂”,McNulty采用x线衍射分析也证明,β一胡萝卜素和番茄红素由扰乱细胞膜的磷脂双分子层,反而有促氧化效应,而虾青素则能很好的稳定细胞膜,呈现强大抗氧化特性,天然虾青素则会附属在自由基体上,永远地终止自由基的破坏生连锁反应,且本身不会变成助氧化剂。
极强的穿透力:虾青素能够穿透血脑屏障、血胰腺屏障、血睾丸屏障这三大人类主要屏障,并且是唯一能穿透血脑屏障的类胡萝卜素,因此是可能作用于脑细胞和眼球视网膜唯一一种类胡萝卜素。
跨膜稳定性:生物体细胞膜是由磷脂双分子层构成的,天然虾青素(超级维生素E)能跨越细胞膜的磷脂双分子层,防止磷脂分子被氧化损害,很好的保障了细胞膜的稳定性,从而显著延长细胞的寿命。
超强吸收性:由于虾青素分子量小——596.8道尔顿,即使加上两端的酯基也不到1 000道尔顿,极易被人体吸收,20分钟可即到达人体各器官。
关节软骨对关节有着重要的缓冲作用。关节被韧性的软骨所覆盖,而软骨的主要成分是胶原蛋白,丝状的胶原蛋白纤维与弹性蛋白及多糖蛋白相互交织形成网状结构,产生一定的强度。若关节软骨硬化,就会出现关节疼痛、变形肿胀、磨损老化。
关节滑液由关节囊和腱鞘分泌,而关节囊和腱鞘都由结缔组织构成,结缔组织的主要成分是胶原蛋白。关节滑液起着润滑关节和营养关节软骨的作用。若关节滑液减少,关节就会因磨损而出现退行性关节炎、骨刺、骨质疏松等,关节软骨长期缺乏关节滑液还会造成骨关节坏死。
运动员及健身人群因运动训练,关节所受负荷较大,关节活动频率高,容易受到损伤。
由于胶原蛋白是关节中软骨组织的主要成分,负责构造软骨组织的框架并将其定型。因此,补充适量的胶原蛋白经过人体吸收,在软骨组织中积累,能够促进软骨细胞合成细胞外大分子基质,维持人体自身软骨组织的自动生成机制,保护关节免于磨损和毁坏,也可预防及改善由各种原因引发的骨关节炎缓解疼痛。胶原蛋白用于药物及食品已有较长的历史。临床研究表明,每日摄入一定的胶原蛋白可减轻膝或髋部骨关节病患者的疼痛,血中羟脯氨酸浓度升高。一家德国研究中心的数据表明,胶原蛋白组与安慰剂组相比有显著治疗效果。对于在研究之初即有重度临床症状的病人,胶原蛋白比安慰剂有更加显著的治疗效果。有报导称14C标记的胶原蛋白将比14C标记的脯氨酸优先聚集在软骨中,这种优先摄取显示胶原蛋白在软骨代谢中有增效作用。
维生素C是一种抗氧化剂维生素,能协同协同虾青素清除过多的氧自由基,保护细胞免受自由基损害。维生素C还能刺激胶原蛋白合成和湿度刺激蛋白多糖的合成,而胶原蛋白和蛋白多糖是关节软骨的重要组成部分。1996年Mcalindon等开展的骨性关节炎临床队列研究表明,适量摄入维生素C可降低骨关节炎病程进展风险3倍,较高剂量摄入维生素C能减少膝关节疼痛的发生。
二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)是人体必需的ω-3不饱和脂肪酸的重要成员,在大脑发育,降低血脂,抑制肿瘤,保护眼睛等领域发挥着重要的作用。调查发现,爱斯基摩人很少患气管炎、风湿性关节炎等慢性疾病,用 DHA 和 EPA 喂饲小鼠,其实验性炎症的水肿程度降低。因其活性能够中和ω-6不饱和脂肪酸等成分代谢中产生的助炎因子,因而也是一种非常有效的协同抗炎和抗氧化成分。DHA含特有的羟基基团是成纤维细胞形成胶原蛋白的重要原料之一,二十二碳六烯酸有助于胶原蛋白的形成,帮助关节软组织修复和再生促进胶原蛋白合成。
现如今应对关节问题,没有一种合适的保护骨关节的营养品,能够避免长期磨损而导致病变,或者由于氧化而导致功能障碍,保证蛋白质补充,维持胶原蛋白正常代谢,减轻关节病患者的疼痛。
发明内容
本发明针对以上情况提出了一种采用抗氧化剂虾青素、胶原蛋白、DHA、DPA合成的营养品,长期服用能够延缓细胞衰老、抑制炎症、保护关节组织、对关节损伤进行修复。并且添加各种辅剂后可制成泡腾片,片剂,粉剂等多种剂型。
本发明所涉及一种保护骨关节的营养品,该营养品为组合物,该组合物原料按照重量比分,包括以下组分:虾青素1~100份,胶原蛋白1~5000份,维生素C1~200份,DHA1~100份,EPA1~100份。
进一步地说:该营养品组合物原料按照重量比分,包括以下成分:虾青素1~25份,胶原蛋白150~10000份,维生素C10~80份,DHA5~80份,EPA10~60份。
进一步地说:该营养品组合物原料按照重量比分,包括以下成分:虾青素1~10份,胶原蛋白150~1000份,维生素C10~50份,DHA10~50份,EPA15~25份,
进一步地说:该营养品组合物原料按照重量比分,包括以下成分:虾青素1~2份,胶原蛋白150~300份,维生素C20~30份,DHA20~50份,EPA15~25份。
更进一步地说:该营养品组合物原料按照重量比分,包括以下成分:虾青素1份,胶原蛋白300份,维生素C30份,DHA50份,EPA25份。
上述虾青素为含有虾青素的食用原料虾青素净含量,原料包括且不仅限于雨生红球藻及其提取物,红发夫酵母产物及其提取物,虾蟹鱼及提取物,化学合成虾青素原料。
上述胶原蛋白为含有胶原蛋白的食用原料胶原蛋白净含量,原料包括且不仅限于牛,猪,鱼以及动植物提取物。
本发明公开一种用于补充抗氧化剂和胶原蛋白的组合物,可加入医学或食品学或保健品学上能接受的载体制成制剂,包括并不限于泡腾片、片剂、丸剂,粉剂、胶囊多种剂型。
本发明公开一种可以延缓细胞老化、抑制关节炎症、增加关节软组织强度及提高滑液的分泌,保护关节组织、对关节损伤进行修复的营养品,以及该养食品在药物、保健品、食品中的应用。
【具体实施方式】
本申请的组合物可加入医药或食品能够接受的载体,研制成制剂;“药学上可接受的”或“食品学上可接受的”或“保健品学上可接受的”的成分,具体指适用于人和/ 或动物而无过度不良副反应( 如毒性、刺激和变态反应) 的,即有合理的效益/ 风险比的物质。“药学上可接受的载体”指用于治疗剂给药的载体,包括各种赋形剂和稀释剂。该术语指这样一些药剂载体:它们本身并不是必要的活性成分,且施用后没有过分的毒性。比如通过药物载体制成颗粒剂、口服液、片剂、胶囊、丸剂等形式,采用现有的工业化生产过程均能实现。也可直接将组合物的原料混合,揉合原料使之成为均匀体,然后通过滚压成型,并切割制成能量棒的形式,最后抽真空包装,这样方便保存和携带,可根据需要在不同的时候进行能量补给。因此,任何通过增加或减少上述载体对组合物进行的可能修正,均涉及本申请发明保护范围。
下面将根据具体实施方式对本发明进行进一步的详细说明。
实施例1:该保护关节的营养品的组合物:虾青素1份,胶原蛋白150份,维生素C30份,DHA50份,EPA25份。该实施例使用含虾青素2%雨生红球藻微囊粉100份(含虾青素1份)。将雨生红球藻提取物经包埋后制成的水分散性微胶囊粉末,并将粉末颗粒作为原料添加硬脂酸镁等赋形剂制成片剂,这种形式的能够充分分散溶解到水溶液中,利于人体吸收。所述原料均为市售购得,并为食品级。所采用的制备方法为食品领域公知技术。
实施例2:该保护关节的营养品的组合物:虾青素25份,胶原蛋白100份,维生素C20份,DHA60份,EPA30份。片剂采用实施例1中的方法制备。
实施例3:该保护关节的营养品的组合物:虾青素10份,胶原蛋白10000份,维生素C200份,DHA150份,EPA75份。虾青素采用含2%虾青素雨生红球藻微囊粉500份(含虾青素10份),其他成分按净含量使用市售粉末制品,添加赋形剂等食品添加剂干燥处理后制成固体饮料粉剂封装。
实施例4:虾青素8份,胶原蛋白15000份,维生素C100份,DHA80份,EPA40份。使用实例3中方法制备。
实施例5:虾青素4份,胶原蛋白5000份,维生素C60份,DHA60份,EPA30份。虾青素使用2%雨生红球藻水分散液200份(含虾青素4份),将雨生红球藻提取物制成水分散液,溶于水,其他成分均使用水溶性原料,及辅料制成营养液或饮料封装。
为检验本发明对关节炎症的恢复效果,进行了如下实验:
受试材料:以实施例1为实验样品,制成片剂,每片含有虾青素2mg,以等体积等重量淀粉片剂为对照样品;
受试对象:在经常参加跑步球类活动的人群中选取有膝关节,踝关节,髋关节疼痛且疼痛程度近似的30名对象;
实验方法:
将实验对象随机分为实验组及对照组两组,自实验日起,每日服用实验样品两次,每次4片,两周后进行痛感测试。
实验期间不服用其他止痛消炎类药物及保健品。
实验期间中止运动,劳作等高负荷活动,但不进行休假静养,照常进行普通工作学习等生活活动。
实验以视觉模拟评分法记录实验数据:
轻微疼痛:1~4
中度疼痛:5~6
严重疼痛:7~9
剧烈疼痛:10
实验周期,7日
试验结果如表1:
实验可看出严重疼痛都有减轻现象,这源自于停止重负荷活动的自然恢复,中度疼痛实验组有9名减弱或痊愈有效率90%,对照组只有4名有效率40%,轻微疼痛实验组全部痊愈有效率100%,对照组只有1名有效率33%。
实验3个月后续跟踪:
痊愈对象中持续服用3名恢复训练后无再发,而对照组均有再发,运动训练时断时续。
上述实验证实本专利声明配方产品对关节炎症有良好的减弱及促进恢复作用,长期服用能保护关节组织,抑制炎症,促进关节损伤的修复。
以上所述,仅是本发明较佳实施例而已,并非对本发明作任何形式上的限制,虽然本发明以较佳实施例揭露如上,然而并非用以限定本发明,任何熟悉本专业的技术人员,在不脱离本发明技术方案范围内,当可利用上述揭示的技术内容做出些许变更或修饰为等同变化的等效实施例,但凡是未脱离本发明技术方案内容,依据本发明技术是指对以上实施例所作的任何简单修改、等同变化与修饰,均属于本发明技术方案的范围内。
Claims (10)
1.一种保护骨关节的营养品,其特征在于,该营养品为组合物,该组合物原料按照重量比分,包括以下组分:虾青素1~100份,胶原蛋白1~5000份,维生素C1~200份,DHA1~100份,EPA1~100份;其中,所述虾青素为含有虾青素的食用原料虾青素净含量,原料包括且不仅限于雨生红球藻及其提取物,所述胶原蛋白为含有胶原蛋白或胶原蛋白肽的食用原料胶原蛋白或胶原蛋白肽净含量,原料包括且不仅限于动植物提取物,所述DHA和EPA为含有DHA和EPA的食用原料DHA和EPA的净含量,原料包括且不仅限于鱼油及其提取物。
2.根据权利要求1所述保护骨关节的营养品,其特征在于,该营养品组合物原料按照重量比分,包括以下成分:虾青素1~80份,胶原蛋白150~5000份,维生素C10~80份,DHA5~80份,EPA10~60份。
3.根据权利要求2所述保护骨关节的营养品,其特征在于,该营养品组合物原料按照重量比分,包括以下成分:虾青素1~10份,胶原蛋白150~3000份,维生素C10~50份,DHA10~50份,EPA15~25份。
4.根据权利要求3所述保护骨关节的营养品,其特征在于,该营养品组合物原料按照重量比分,包括以下成分:虾青素1~2份,胶原蛋白150~1000份,维生素C20~30份,DHA20~50份,EPA15~25份。
5.根据权利要求1所述保护骨关节的营养品,其特征在于,该营养品组合物原料按照重量比分,包括以下成分:虾青素1份,胶原蛋白300份,维生素C30份,DHA 50份,EPA 25份。
6.根据权利要求1-5任一所述保护骨关节的营养品,其特征在于,任选包括医药和/或食品可接受的载体。
7.根据权利要求1-5任一所述保护骨关节的营养品,其特征在于,,原料包括且不仅限于红发夫酵母产物及其提取物,虾蟹鱼及提取物,化学合成虾青素原料。
8.根据权利要求1-5任一所述保护骨关节的营养品,其特征在于,用于制备如下功效的食品或药品中,并进行商业开发,对受试者施用所述组合物后,可预防及缓解运动后的关节炎症。
9.根据权利要求1~5任一项的组合物所生产的相关制品,包括但不限于片剂、胶囊剂、粉剂、颗粒剂、泡腾剂、饮料、合剂或口服液,饮料。
10.一种保护骨关节的方法,所述方法包括对受试者施用权利要求1~5任一项的组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711110451.0A CN107788526A (zh) | 2017-11-12 | 2017-11-12 | 一种保护骨关节的营养品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711110451.0A CN107788526A (zh) | 2017-11-12 | 2017-11-12 | 一种保护骨关节的营养品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107788526A true CN107788526A (zh) | 2018-03-13 |
Family
ID=61534897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711110451.0A Pending CN107788526A (zh) | 2017-11-12 | 2017-11-12 | 一种保护骨关节的营养品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107788526A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108741054A (zh) * | 2018-05-25 | 2018-11-06 | 何会平 | 一种用于保护骨关节的运动营养品 |
IT201900024907A1 (it) * | 2019-12-19 | 2021-06-19 | Kolinpharma S P A | Composizione multicomponente comprendente un collagene, resveratrolo e astaxantina e suo uso per il trattamento di tendinopatie |
CN113368220A (zh) * | 2021-07-05 | 2021-09-10 | 云南维他源生物科技有限公司 | 一种ahco组合物及其制剂与应用 |
-
2017
- 2017-11-12 CN CN201711110451.0A patent/CN107788526A/zh active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108741054A (zh) * | 2018-05-25 | 2018-11-06 | 何会平 | 一种用于保护骨关节的运动营养品 |
IT201900024907A1 (it) * | 2019-12-19 | 2021-06-19 | Kolinpharma S P A | Composizione multicomponente comprendente un collagene, resveratrolo e astaxantina e suo uso per il trattamento di tendinopatie |
WO2021124253A1 (en) * | 2019-12-19 | 2021-06-24 | Kolinpharma S.P.A. | A multicomponent composition comprising a collagen, resveratrol and astaxanthin and the use thereof for the treatment of tendinopathies |
CN115335042A (zh) * | 2019-12-19 | 2022-11-11 | 科林制药公司 | 包含胶原蛋白、白藜芦醇和虾青素的多成分组合物及其用于治疗肌腱病的应用 |
CN115335042B (zh) * | 2019-12-19 | 2024-05-10 | 科林制药公司 | 包含胶原蛋白、白藜芦醇和虾青素的多成分组合物及其用于治疗肌腱病的应用 |
CN113368220A (zh) * | 2021-07-05 | 2021-09-10 | 云南维他源生物科技有限公司 | 一种ahco组合物及其制剂与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE102008036954B4 (de) | Verwendung einer Aminozucker enthaltenden Zusammensetzung | |
US8524980B2 (en) | Composition and method to alleviate joint pain | |
US8703174B2 (en) | Joint preserving nutritional vitamin, mineral and herbal pet supplement | |
US20120004157A1 (en) | Hydroxyproline compositions and uses thereof | |
CN103561753A (zh) | 用于促进骨骼和关节生长、修复、和维持的膳食增补剂 | |
KR20120115965A (ko) | 안구 건조의 완화를 위한 영양 보충제 | |
CN110859247A (zh) | 组合物、制备方法及其在制备治疗宠物关节疾病药品、保健品及食品中的应用 | |
CN107788526A (zh) | 一种保护骨关节的营养品 | |
US10653655B2 (en) | Composition for preventing or improving peripheral neuropathy | |
Binsi et al. | Functional and nutraceutical ingredients from marine resources | |
EP3461479A1 (en) | Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions | |
US20040254095A1 (en) | Supplement for treating musculoskeletal disorders | |
JP7382085B2 (ja) | 関節機能改善組成物 | |
US11730713B2 (en) | Composition for preventing or improving nociceptive pain | |
Stephen et al. | Seafood nutraceuticals: Health benefits and functional properties | |
RU2284707C1 (ru) | Биологически активная добавка к пище | |
Birlik | Nutritional Supplements for Musculoskeletal Health | |
RU2672914C1 (ru) | Специализированный, функциональный, антиоксидантный комплекс | |
Tkacheva et al. | Sulfur (S)–Body & Health Importance+ Top 20 Sources | |
Kataki et al. | Nutrition and Healthy Aging | |
CZ37101U1 (cs) | Potravinový doplněk s kolagenem s jahodou | |
DE102016002654A1 (de) | Verwendung einer Gelatinematrix zur Sicherstellung der Funktionalität bzw zur Qualitätsverbesserung der Anwendung von (einem oder mehreren) Arznei- oder Nahrungsergänzungsmittel(n) zur Behandlung und/oder Prophylaxe von - aber nicht beschränkt auf - Mobilitätsproblemen, Knochenerkrankungen, Bindegewebsschwäche, Immunsystemschwäche, Regenerierung nach sportlicher Betätigung und/oder Krankheit durch Einschließung der Wirkstoffe in Selbiger. | |
CN108041591A (zh) | 一种胃粘膜用组合物及其制备方法 | |
Bansal et al. | ROLE OF KRILL OIL SUPPLEMENTATION IN DIABETIC NEUROPATHY PATIENTS–A RANDOMIZED CONTROL TRIAL | |
DEMİRTÜRK et al. | COLLAGEN SUPPLEMENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180313 |